Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses
and limited treatment interventions. Recently, comprehensive molecular profiles of lung …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Rearranged during transfection (RET) is involved in the physiological development of some
organ systems. Activating RET alterations via either gene fusions or point mutations are …

The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …

Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations
have been identified as oncogenic in multiple malignancies. RET gene rearrangements …

Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective
RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung …